Cencora Inc. reported gross profit of $7.9 billion for its U.S. Healthcare Solutions segment for the fiscal year ended September 30, 2025, a 23.1% increase from the previous year. Gross profit for the International Healthcare Solutions segment was $3.3 billion, representing a 0.2% decrease compared to the prior year. Total restructuring and other expenses for the year were $229.4 million, primarily related to workforce reductions and business transformation initiatives, including costs associated with the company's rebranding to Cencora. The company also noted a cybersecurity event in fiscal 2024 and completed the acquisition of RCA in January 2025. Depreciation expense increased by 15.3%, while amortization expense decreased by 16.1%. Litigation and opioid-related expenses were recorded in both fiscal years, with a significant accrual in 2024 related to prescription opioid distribution litigation. No key contracts are scheduled to expire in the next twelve months.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cencora Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140859-25-000131), on November 25, 2025, and is solely responsible for the information contained therein.
Comments